Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan.
Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Taipei, Taiwan; Chang Gung University College of Medicine, Taipei, Taiwan.
Ann Thorac Surg. 2014 Jun;97(6):1939-44. doi: 10.1016/j.athoracsur.2014.02.021. Epub 2014 Mar 28.
Extracorporeal membrane oxygenation (ECMO) has been utilized for patients in critical condition, including life-threatening respiratory failure and postcardiotomy cardiogenic shock. This study analyzed the outcomes of patients with acute respiratory distress syndrome (ARDS) treated by ECMO and identified the relationship between prognosis and urine output (UO) obtained on the first day of ECMO support.
This study reviewed the medical records of 81 ARDS patients after ECMO support on a specialized cardiovascular surgery intensive care unit of a tertiary care university hospital between May 2006 and December 2011. Demographic, clinical, and laboratory variables were retrospectively collected as survival predictors.
The overall mortality rate was 55.5%. A multiple logistic regression analysis indicated that the Acute Physiology and Chronic Health Evaluation II (APACHE II) score, mean arterial pressure, platelet count, and UO on day 1 of ECMO support were independent risk factors for hospital mortality. By using the areas under the receiver operating characteristic (AUROC) curve, UO obtained on the first day of ECMO support demonstrated good discriminative power (AUROC 0.754 ± 0.056, p < 0.001). Urine output had the best discriminative power, the best Youden index, and the highest overall correctness of prediction. Cumulative survival rates at the 6-month follow-up differed significantly (p < 0.001) for UO 1,432 mL or greater on day 1 of ECMO support versus those with UO less than 1,432 mL on day 1 of ECMO support.
In ARDS patients receiving ECMO support, UO obtained on the first day of ECMO support showed good prognostic ability in predicting hospital mortality.
体外膜肺氧合(ECMO)已被用于治疗危急重症患者,包括威胁生命的呼吸衰竭和心脏手术后的心源性休克。本研究分析了接受 ECMO 治疗的急性呼吸窘迫综合征(ARDS)患者的结局,并确定了 ECMO 支持的第一天获得的尿量(UO)与预后之间的关系。
本研究回顾性分析了 2006 年 5 月至 2011 年 12 月在一家三级大学医院的心血管外科重症监护病房接受 ECMO 支持的 81 例 ARDS 患者的病历。收集了人口统计学、临床和实验室变量作为生存预测因素。
总体死亡率为 55.5%。多因素逻辑回归分析表明,急性生理学和慢性健康评估 II(APACHE II)评分、平均动脉压、血小板计数和 ECMO 支持的第一天的 UO 是医院死亡率的独立危险因素。使用接受者操作特征(ROC)曲线下面积(AUROC),ECMO 支持的第一天获得的 UO 具有良好的区分能力(AUROC 0.754 ± 0.056,p < 0.001)。UO 具有最佳的区分能力、最佳的约登指数和最高的总体预测正确性。6 个月随访时,ECMO 支持的第一天 UO 达到或超过 1432 mL 与第一天 UO 小于 1432 mL 的患者的累积生存率差异有统计学意义(p < 0.001)。
在接受 ECMO 支持的 ARDS 患者中,ECMO 支持的第一天获得的 UO 能够很好地预测医院死亡率。